- Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
-
Yoneoka Y, Amano T, Takahashi A, Nishimura H, Deguchi M, Yamanaka H, Tanaka Y, Tsuji S, Murakami T
- KMID: 2561016
- Obstet Gynecol Sci.
- 2024 Nov;67(6):534-540.
- doi: 10.5468/ogs.24075
Objective There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the... -
- CITED
-
- Close
- SHARE
-
- Close
- The baseline recurrence risk of patients with intermediate-risk cervical cancer
-
Yoneoka Y, Kato MK, Tanase Y, Uno M, Ishikawa M, Murakami T, Kato T
- KMID: 2513952
- Obstet Gynecol Sci.
- 2021 Mar;64(2):226-233.
- doi: 10.5468/ogs.20243
Objective This study aimed to investigate the prognosis of patients with intermediate-risk cervical cancer and to evaluate the necessity of adjuvant therapy. Methods We conducted a retrospective chart review of patients with stage... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma
-
Yoneoka Y, Yoshida H, Ishikawa M, Shimizu H, Uehara T, Murakami T, Kato T
- KMID: 2429576
- J Gynecol Oncol.
- 2019 Jan;30(1):e7.
- doi: 10.3802/jgo.2019.30.e7
OBJECTIVE: Gynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients who show favorable prognosis than locally advanced or metastatic disease patients. This study aimed to elucidate prognostic factors... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
-
Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T
- KMID: 2457157
- J Gynecol Oncol.
- 2019 Sep;30(5):e81.
- doi: 10.3802/jgo.2019.30.e81
OBJECTIVE: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete... -
- CITED
-
- Close
- SHARE
-
- Close
